stockrowRigel Pharmaceuticals, Inc. (RIGL) vs Syndax Pharmaceuticals, Inc. (SNDX)
- Rigel Pharmaceuticals, Inc. RIGL 39.59 −13.39%
- Syndax Pharmaceuticals, Inc. SNDX 9.54 +1.81%
Rigel Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc. are both Biotechnology companies. Rigel Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc. are of similar size ($853.9M and $843.6M). Syndax Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.4×. Syndax Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 159.5% against 2.18%. Rigel Pharmaceuticals, Inc. has the higher net margin (106.6% vs −72.4%) and the higher return on invested capital (13.7% vs −83.4%). Across the 17 metrics below, Rigel Pharmaceuticals, Inc. leads on 12 and Syndax Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | RIGL | SNDX | Biotechnology median |
|---|---|---|---|
| Gross margin | 89.64% | 92.21% | 68.51% |
| Operating margin | 26.28% | (61.72%) | 0.00% |
| Net margin | 106.59% | (72.38%) | 0.00% |
| Free cash flow margin | 31.20% | (61.36%) | 0.00% |
| Return on equity | 109.18% | (426.43%) | (51.96%) |
| Return on assets | 80.16% | (33.67%) | (46.06%) |
| Return on invested capital | 13.69% | (83.42%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack